UA73609C2 - 1-aminoalkylcyclohexanes as trypanocides - Google Patents

1-aminoalkylcyclohexanes as trypanocides Download PDF

Info

Publication number: UA73609C2
Authority: UA; Ukraine
Prior art keywords: amino; trans; methyl; cis; propyl
Prior art date: 2000-09-19

Application number

UA2003043559A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merz Pharma Gmbh & Co Kgaa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-19

Filing date

2001-09-14

Publication date

2005-08-15

2001-09-14 Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa

2005-08-15 Publication of UA73609C2 publication Critical patent/UA73609C2/uk

Links

230000000654 trypanocidal effect Effects 0.000 title claims abstract description 16
239000002690 trypanocidal agent Substances 0.000 title claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
230000001099 anti-trypanosomal effect Effects 0.000 claims abstract description 10
239000003795 chemical substances by application Substances 0.000 claims abstract description 8
150000001875 compounds Chemical class 0.000 claims description 48
239000000203 mixture Substances 0.000 claims description 44
238000000034 method Methods 0.000 claims description 33
150000003839 salts Chemical class 0.000 claims description 13
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 12
125000000217 alkyl group Chemical group 0.000 claims description 12
230000003287 optical effect Effects 0.000 claims description 12
241001465754 Metazoa Species 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
150000004677 hydrates Chemical class 0.000 claims description 11
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 claims description 10
KONIYTHNVWYBMP-UHFFFAOYSA-N ethylcyclohexane Chemical compound [CH2-]C[C+]1CCCCC1 KONIYTHNVWYBMP-UHFFFAOYSA-N 0.000 claims description 10
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
239000001257 hydrogen Substances 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
125000003277 amino group Chemical group 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
239000000969 carrier Substances 0.000 claims description 5
238000011161 development Methods 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
NEVCGYUBKUPZRL-UHFFFAOYSA-N (3,3,5,5-tetramethylcyclohexyl)methanamine Chemical compound CC1(C)CC(CN)CC(C)(C)C1 NEVCGYUBKUPZRL-UHFFFAOYSA-N 0.000 claims description 4
WCBGLHDVUJFUDO-UHFFFAOYSA-N 1,3,3-trimethyl-5,5-dipropylcyclohexan-1-amine Chemical compound CCCC1(CCC)CC(C)(C)CC(C)(N)C1 WCBGLHDVUJFUDO-UHFFFAOYSA-N 0.000 claims description 4
QTXWDXKTMLBHIW-UHFFFAOYSA-N 1,3,3-trimethylcyclohexan-1-amine Chemical compound CC1(C)CCCC(C)(N)C1 QTXWDXKTMLBHIW-UHFFFAOYSA-N 0.000 claims description 4
YDBHSDRXUCPTQQ-UHFFFAOYSA-N 1-methylcyclohexan-1-amine Chemical compound CC1(N)CCCCC1 YDBHSDRXUCPTQQ-UHFFFAOYSA-N 0.000 claims description 4
OIHULWBOFIEYPQ-UHFFFAOYSA-N 2-(3,3,5,5-tetramethylcyclohexyl)ethanamine Chemical compound CC1(C)CC(CCN)CC(C)(C)C1 OIHULWBOFIEYPQ-UHFFFAOYSA-N 0.000 claims description 4
OMYKWZGACJRFAJ-UHFFFAOYSA-N 3,3,5,5-tetramethyl-1-propylcyclohexan-1-amine Chemical compound CCCC1(N)CC(C)(C)CC(C)(C)C1 OMYKWZGACJRFAJ-UHFFFAOYSA-N 0.000 claims description 4
JINZKAFNDLFUEW-UHFFFAOYSA-N 3-ethyl-1,3,5,5-tetramethylcyclohexan-1-amine Chemical compound CCC1(C)CC(C)(C)CC(C)(N)C1 JINZKAFNDLFUEW-UHFFFAOYSA-N 0.000 claims description 4
DEDZSLCZHWTGOR-UHFFFAOYSA-N n-propylcyclohexane Natural products CCCC1CCCCC1 DEDZSLCZHWTGOR-UHFFFAOYSA-N 0.000 claims description 4
DZFVMEAYTQZHGF-UHFFFAOYSA-N propylcyclohexane Chemical compound CCC[C]1CCCCC1 DZFVMEAYTQZHGF-UHFFFAOYSA-N 0.000 claims description 4
KBPLVGBTXYNDFW-UHFFFAOYSA-N 3-ethyl-1,3-dimethylcyclohexan-1-amine Chemical compound CCC1(C)CCCC(C)(N)C1 KBPLVGBTXYNDFW-UHFFFAOYSA-N 0.000 claims description 3
125000002947 alkylene group Chemical group 0.000 claims description 3
BADMBUCXLGEWNJ-UHFFFAOYSA-N 1,3-dimethyl-3-propylcyclohexan-1-amine Chemical compound CCCC1(C)CCCC(C)(N)C1 BADMBUCXLGEWNJ-UHFFFAOYSA-N 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
RTRXNNYIVXZLDQ-UHFFFAOYSA-N 1,3,3,5-tetramethyl-5-propylcyclohexan-1-amine Chemical compound CCCC1(C)CC(C)(C)CC(C)(N)C1 RTRXNNYIVXZLDQ-UHFFFAOYSA-N 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
201000002311 trypanosomiasis Diseases 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract 1
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 51
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 26
239000004480 active ingredient Substances 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 11
230000000694 effects Effects 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000007788 liquid Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
239000002775 capsule Substances 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
-1 optical isomers Chemical class 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000002105 nanoparticle Substances 0.000 description 5
239000008213 purified water Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
208000009182 Parasitemia Diseases 0.000 description 3
208000030852 Parasitic disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229940125681 anticonvulsant agent Drugs 0.000 description 3
239000001961 anticonvulsive agent Substances 0.000 description 3
229940075614 colloidal silicon dioxide Drugs 0.000 description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
244000045947 parasite Species 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
QEGNUYASOUJEHD-UHFFFAOYSA-N 1,1-dimethylcyclohexane Chemical compound CC1(C)CCCCC1 QEGNUYASOUJEHD-UHFFFAOYSA-N 0.000 description 2
NBZGMQHFDNUNRQ-UHFFFAOYSA-N 3,3-diethyl-1,5,5-trimethylcyclohexan-1-amine Chemical compound CCC1(CC)CC(C)(C)CC(C)(N)C1 NBZGMQHFDNUNRQ-UHFFFAOYSA-N 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000002609 medium Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000011257 shell material Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940098465 tincture Drugs 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
KQYFWNDUFOBYGY-UHFFFAOYSA-N 1,2,2,3,3-pentamethylcyclohexan-1-amine Chemical compound CC1(C)CCCC(C)(N)C1(C)C KQYFWNDUFOBYGY-UHFFFAOYSA-N 0.000 description 1
PMNUOTQOFZGNNQ-UHFFFAOYSA-N 1,3,5-trimethylcyclohexan-1-amine Chemical compound CC1CC(C)CC(C)(N)C1 PMNUOTQOFZGNNQ-UHFFFAOYSA-N 0.000 description 1
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
YKLPCZMZROZLJA-UHFFFAOYSA-N 1-ethyl-3,3,5,5-tetramethylcyclohexan-1-amine Chemical compound CCC1(N)CC(C)(C)CC(C)(C)C1 YKLPCZMZROZLJA-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000000230 African Trypanosomiasis Diseases 0.000 description 1
208000008316 Arsenic Poisoning Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
240000001890 Ribes hudsonianum Species 0.000 description 1
235000016954 Ribes hudsonianum Nutrition 0.000 description 1
235000001466 Ribes nigrum Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000223105 Trypanosoma brucei Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
239000000470 constituent Chemical group 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
230000006378 damage Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000007720 emulsion polymerization reaction Methods 0.000 description 1
JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
229950010048 enbucrilate Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
208000029080 human African trypanosomiasis Diseases 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036512 infertility Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001728 melarsoprol Drugs 0.000 description 1
239000000155 melt Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000005180 public health Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000888 rimantadine Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
201000002612 sleeping sickness Diseases 0.000 description 1
235000019997 soju Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
239000001043 yellow dye Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2003043559A 2000-09-19 2001-09-14 1-aminoalkylcyclohexanes as trypanocides UA73609C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/664,629 US6602862B1 (en)	2000-09-19	2000-09-19	1-Amino-alkylcyclohexanes as trypanocidal agents
PCT/EP2001/010731 WO2002024186A1 (en)	2000-09-19	2001-09-14	1-amino-alkylcyclohexanes as trypanocidal agents

Publications (1)

Publication Number	Publication Date
UA73609C2 true UA73609C2 (en)	2005-08-15

Family

ID=24666769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003043559A UA73609C2 (en)	2000-09-19	2001-09-14	1-aminoalkylcyclohexanes as trypanocides

Country Status (24)

Country	Link
US (1)	US6602862B1 (de)
EP (1)	EP1318800B1 (de)
JP (1)	JP2004509144A (de)
KR (1)	KR100570373B1 (de)
CN (1)	CN1283239C (de)
AR (1)	AR030750A1 (de)
AT (1)	ATE287708T1 (de)
AU (2)	AU8774001A (de)
CA (1)	CA2420056C (de)
CZ (1)	CZ2003776A3 (de)
DE (1)	DE60108650T2 (de)
EA (1)	EA005499B1 (de)
ES (1)	ES2233679T3 (de)
GE (1)	GEP20053480B (de)
HU (1)	HUP0302497A3 (de)
IL (2)	IL154867A0 (de)
MX (1)	MXPA03001790A (de)
NO (1)	NO20031239D0 (de)
PL (1)	PL361428A1 (de)
PT (1)	PT1318800E (de)
TW (1)	TWI297605B (de)
UA (1)	UA73609C2 (de)
WO (1)	WO2002024186A1 (de)
ZA (1)	ZA200107649B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6444702B1 (en)	2000-02-22	2002-09-03	Neuromolecular, Inc.	Aminoadamantane derivatives as therapeutic agents
EP2448901A1 (de) *	2009-06-29	2012-05-09	Merz Pharma GmbH & Co. KGaA	Verfahren zur herstellung von 3,3,5,5-tetramethylcyclohexanon
CN102241678B (zh)	2011-04-26	2014-10-29	辽宁利锋科技开发有限公司	含有脂环结构化合物的抗肿瘤作用与应用
EP2826856B9 (de) *	2013-07-16	2016-05-04	Sia Latima	Genetisch stabiles onkolytisches RNA-Virus, Verfahren zur Herstellung und Verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE150448T1 (de)	1993-04-13	1997-04-15	Ciba Geigy Ag	Ornithine-decarboxylase hemmende cyclische aminooxy-verbindungen
UA61962C2 (uk)	1997-06-30	2003-12-15	Мерц Фарма Гмбх Унд Ко. Кгаа	Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US6071966A (en) *	1997-06-30	2000-06-06	Merz + Co. Gmbh & Co.	1-amino-alkylcyclohexane NMDA receptor antagonists
US6093743A (en) *	1998-06-23	2000-07-25	Medinox Inc.	Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

2000
- 2000-09-19 US US09/664,629 patent/US6602862B1/en not_active Expired - Fee Related
2001
- 2001-09-04 TW TW090121900A patent/TWI297605B/zh active
- 2001-09-14 WO PCT/EP2001/010731 patent/WO2002024186A1/en not_active Ceased
- 2001-09-14 AT AT01967349T patent/ATE287708T1/de not_active IP Right Cessation
- 2001-09-14 HU HU0302497A patent/HUP0302497A3/hu unknown
- 2001-09-14 EP EP01967349A patent/EP1318800B1/de not_active Expired - Lifetime
- 2001-09-14 PL PL36142801A patent/PL361428A1/xx unknown
- 2001-09-14 CN CNB018159524A patent/CN1283239C/zh not_active Expired - Fee Related
- 2001-09-14 IL IL15486701A patent/IL154867A0/xx unknown
- 2001-09-14 ES ES01967349T patent/ES2233679T3/es not_active Expired - Lifetime
- 2001-09-14 MX MXPA03001790A patent/MXPA03001790A/es active IP Right Grant
- 2001-09-14 AU AU8774001A patent/AU8774001A/xx active Pending
- 2001-09-14 JP JP2002528257A patent/JP2004509144A/ja active Pending
- 2001-09-14 EA EA200300388A patent/EA005499B1/ru not_active IP Right Cessation
- 2001-09-14 PT PT01967349T patent/PT1318800E/pt unknown
- 2001-09-14 KR KR1020037004009A patent/KR100570373B1/ko not_active Expired - Fee Related
- 2001-09-14 AU AU2001287740A patent/AU2001287740B2/en not_active Ceased
- 2001-09-14 CA CA002420056A patent/CA2420056C/en not_active Expired - Fee Related
- 2001-09-14 CZ CZ2003776A patent/CZ2003776A3/cs unknown
- 2001-09-14 DE DE60108650T patent/DE60108650T2/de not_active Expired - Fee Related
- 2001-09-14 UA UA2003043559A patent/UA73609C2/uk unknown
- 2001-09-14 GE GE5127A patent/GEP20053480B/en unknown
- 2001-09-17 ZA ZA200107649A patent/ZA200107649B/xx unknown
- 2001-09-17 AR ARP010104388A patent/AR030750A1/es unknown
2003
- 2003-03-11 IL IL154867A patent/IL154867A/en not_active IP Right Cessation
- 2003-03-18 NO NO20031239A patent/NO20031239D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TWI297605B (en)	2008-06-11
IL154867A (en)	2009-08-03
HK1058151A1 (en)	2004-05-07
CN1461213A (zh)	2003-12-10
US6602862B1 (en)	2003-08-05
DE60108650T2 (de)	2006-01-19
CN1283239C (zh)	2006-11-08
HUP0302497A3 (en)	2005-08-29
AU8774001A (en)	2002-04-02
AU2001287740B2 (en)	2005-01-27
DE60108650D1 (en)	2005-03-03
JP2004509144A (ja)	2004-03-25
PL361428A1 (en)	2004-10-04
EP1318800B1 (de)	2005-01-26
ZA200107649B (en)	2002-05-14
EA005499B1 (ru)	2005-02-24
EA200300388A1 (ru)	2003-08-28
AR030750A1 (es)	2003-09-03
MXPA03001790A (es)	2004-11-01
CA2420056C (en)	2007-11-13
GEP20053480B (en)	2005-03-25
KR100570373B1 (ko)	2006-04-24
CA2420056A1 (en)	2002-03-28
ES2233679T3 (es)	2005-06-16
IL154867A0 (en)	2003-10-31
CZ2003776A3 (en)	2004-03-17
WO2002024186A1 (en)	2002-03-28
ATE287708T1 (de)	2005-02-15
HUP0302497A2 (hu)	2003-12-29
NO20031239L (no)	2003-03-18
PT1318800E (pt)	2005-05-31
NO20031239D0 (no)	2003-03-18
KR20030045079A (ko)	2003-06-09
EP1318800A1 (de)	2003-06-18

Publication	Publication Date	Title
KR0180019B1 (ko)	1999-03-20	개량된 화학적 화합물
JP5393679B2 (ja)	2014-01-22	アレナウイルス感染症を治療するための抗ウイルス薬
US20200093841A1 (en)	2020-03-26	Broad Spectrum Antiviral and Methods of Use
JP4159351B2 (ja)	2008-10-01	５−ｈｔ３受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての１−アミノ−アルキルシクロヘキサン
JP2025011312A (ja)	2025-01-23	ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
JPS5910585A (ja)	1984-01-20	スピロスクシンイミド誘導体のアルツハイマ−型痴「ほう」の治療における使用
EP1304108A2 (de)	2003-04-23	Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
EP1318800B1 (de)	2005-01-26	1-amino-alkylcyclohexanederivate als trypanocide mittel
JP4063341B2 (ja)	2008-03-19	緑内障治療剤及び眼圧降下剤
RO119280B1 (ro)	2004-07-30	Asociere farmaceutică, compoziţie farmaceutică şi utilizarea asocierii farmaceutice pentru tratamentul şi/sau profilaxia unei infecţii cauzate de protozoare parazite sau a unei infecţii cauzate de pneumocystis carinii
AU2001287740A1 (en)	2002-06-20	1-amino-alkylcyclohexanes as trypanocidal agents
GB2291592A (en)	1996-01-31	Pharmaceutical compositions comprising a bicycloheptane derivative
US4857529A (en)	1989-08-15	Interferon inducing, anti-vaccinia, and/or anti-influenza compositions
US4322555A (en)	1982-03-30	Nonaprenylamine derivatives
JPS6116A (ja)	1986-01-06	有機化合物に関する改良
US4393209A (en)	1983-07-12	Decaprenylamine derivatives
US8791110B2 (en)	2014-07-29	Anti-arenaviral compounds
GB2065110A (en)	1981-06-24	Decaprenylamine Derivatives
HU179753B (en)	1982-12-28	Process for producting synergetic pharmaceutical compositions of citostatic activity
EP1199078A1 (de)	2002-04-24	Analgetika
WO1993023066A1 (fr)	1993-11-25	Promoteur de croissance de plaquettes